{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:36:52Z","timestamp":1768700212776,"version":"3.49.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"R Huelin, M Stokes, Y Guo, M Hoog and T Bhagnani"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Sci. OA"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.4155\/fsoa-2018-0049","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T11:38:35Z","timestamp":1532000315000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":26,"title":["Systematic Review of Therapy Used in Relapsed Or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma"],"prefix":"10.1080","volume":"4","author":[{"given":"Aaron","family":"Galaznik","sequence":"first","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA 02139, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Huelin","sequence":"additional","affiliation":[{"name":"Meta Research, Evidera, 500 Totten Pond Road, Fifth Floor, Waltham, MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stokes","sequence":"additional","affiliation":[{"name":"Data Analytics, Evidera, 7575 Trans-Canada Highway, Suite 404, St-Laurent, Quebec H4T 1V6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelan","family":"Guo","sequence":"additional","affiliation":[{"name":"Meta Research, Evidera, Metro Building, 6th Floor, 1 Butterwick, London W6 8DL, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Hoog","sequence":"additional","affiliation":[{"name":"Modelling and Simulation, Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD 20814, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Bhagnani","sequence":"additional","affiliation":[{"name":"Data Analytics, Evidera, 500 Totten Pond Road, Fifth Floor, Waltham, MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Bell","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA 02139, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Shou","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA 02139, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32407-2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0130"},{"key":"e_1_3_4_5_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) B-cell Lymphomas version 7.2017. (2017). www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-524108"},{"key":"e_1_3_4_7_1","unstructured":"PDQ\u00ae Adult Treatment Editorial Board. Adult non-Hodgkin lymphoma treatment (PDQ\u00ae)\u2013health professional version. (2017). www.cancer.gov\/types\/lymphoma\/hp\/adult-nhl-treatment-pdq."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a001719"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1106536"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.4"},{"key":"e_1_3_4_11_1","volume-title":"American Society of Hematology (ASH) 56th Annual Meeting and Exposition","author":"Avivi I","year":"2014","unstructured":"Avivi I, Boumendil A, Finel HH et al. Autologous stem cell transplantation for primary mediastinal B cell lymphoma in the rituximab era: a retrospective study by the EBMT Lymphoma Working Party. American Society of Hematology (ASH) 56th Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014 (Abstract 1195)."},{"key":"e_1_3_4_12_1","volume-title":"American Society of Hematology (ASH) 57th Annual Meeting and Exposition","author":"Farooq F","year":"2015","unstructured":"Farooq F, Maurer MJ, Ansell SM et al. Treatment patterns and outcomes of DLBCL after failure of front-line immunochemotherapy. American Society of Hematology (ASH) 57th Annual Meeting and Exposition. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 2683)."},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14046"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12379"},{"key":"e_1_3_4_16_1","volume-title":"American Society of Hematology (ASH) 57th Annual Meeting and Exposition","author":"Herrera AF","year":"2015","unstructured":"Herrera AF, Mei MG, Low L et al. Double expressing (MYC\/BCL2) and double-hit diffuse large B-cell lymphomas have inferior survival following autologous stem cell transplantation. Presented at: American Society of Hematology (ASH) 57th Annual Meeting and Exposition. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 522)."},{"key":"e_1_3_4_17_1","volume-title":"American Society of Hematology (ASH) 57th Annual Meeting and Exposition","author":"Khouri I","year":"2015","unstructured":"Khouri I, Sui D, Turturro F et al. In-vivo purging with rituximab (R) followed by Z\/BEAM vs BEAM\/R autologous stem cell conditioning for relapsed diffuse large B-cell lymphoma (DLBCL) patients (pts): mature results from a combined analysis of 3 trials. Presented at: American Society of Hematology (ASH) 57th Annual Meeting and Exposition. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 3192)."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.028"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.223"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.06.003"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5203"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1395-9"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.286"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw124"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.83"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2271-1"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2289-y"},{"issue":"21","key":"e_1_3_4_28_1","article-title":"Outcomes following allogeneic stem cell transplantation (alloSCT) in patients with primary mediastinal (PMBL), germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas (DLBCL). Presented at: American Society of Hematology (ASH) 56th Annual Meeting and Exposition, 6\u20139 December 2014, San Francisco, CA","volume":"124","author":"Khouri I","year":"2014","unstructured":"Khouri I, Saliba R, Xu-Monette Z et al. Outcomes following allogeneic stem cell transplantation (alloSCT) in patients with primary mediastinal (PMBL), germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas (DLBCL). Presented at: American Society of Hematology (ASH) 56th Annual Meeting and Exposition, 6\u20139 December 2014, San Francisco, CA. Blood 124(21), Abstract 2563 (2014).","journal-title":"Blood"},{"key":"e_1_3_4_29_1","volume-title":"American Society of Hematology (ASH) 56th Annual Meeting and Exposition","author":"Czucman MS","year":"2014","unstructured":"Czucman MS, Davis A, Linton KM et al. Phase 2\/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed\/refractory DLBCL. Presented at: American Society of Hematology (ASH) 56th Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014 (Abstract 628)."},{"key":"e_1_3_4_30_1","volume-title":"American Society of Hematology (ASH) 57th Annual Meeting and Exposition","author":"Isidori A","year":"2015","unstructured":"Isidori A, Guidi S, Scalzulli PR et al. Benda-beam high-dose therapy prior to auto-SCT is effective in resistant\/relapsed DLBCL. Presented at: American Society of Hematology (ASH) 57th Annual Meeting and Exposition. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 1999)."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2896-2"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.348"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13954"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.04.014"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.03.005"},{"key":"e_1_3_4_36_1","volume-title":"American Society of Hematology (ASH) 57th Annual Meeting and Exposition","author":"Pott C","year":"2015","unstructured":"Pott C, Belada D, Danesi N et al. Analysis of minimal residual disease in follicular lymphoma patients in gadolin, a Phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed\/refractory indolent non-Hodgkin lymphoma. Presented at: American Society of Hematology (ASH) 57th Annual Meeting and Exposition. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 3978)."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481341"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4474"},{"key":"e_1_3_4_39_1","volume-title":"American Society of Hematology (ASH) 57th Annual Meeting and Exposition","author":"Sureda A","year":"2015","unstructured":"Sureda A, Zhang MJ, Dreger P et al. Allogeneic stem cell transplantation for relapsed\/refractory (R\/R) follicular lymphoma (FL). A joint study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Presented at: American Society of Hematology (ASH) 57th Annual Meeting and Exposition. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 198)."},{"key":"e_1_3_4_40_1","volume-title":"American Society of Hematology (ASH) 57th Annual Meeting and Exposition","author":"Sorigu\u00e9 M","year":"2015","unstructured":"Sorigu\u00e9 M, Sancho JM, Mercadal S et al. Prevalence, predictive factors therapy and outcome of patients with follicular lymphoma refractory to first line immunochemotherapy. Presented at: American Society of Hematology (ASH) 57th Annual Meeting and Exposition. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 1510)."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.911859"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0198"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5477"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.002"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.3328"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_4_52_1","volume-title":"American Society of Hematology (ASH) 59th Annual Meeting and Exposition","author":"Schuster SJ","year":"2017","unstructured":"Schuster SJ, Bishop MR, Tam CS et al. Primary analysis of Juliet: a global, pivotal, Phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Presented at: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. Atlanta, GA, USA, 9\u201312 December 2017 (Abstract 577)."}],"container-title":["Future Science OA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fsoa-2018-0049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:58Z","timestamp":1719125218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fsoa-2018-0049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.4155\/fsoa-2018-0049"],"URL":"https:\/\/doi.org\/10.4155\/fsoa-2018-0049","relation":{},"ISSN":["2056-5623"],"issn-type":[{"value":"2056-5623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifso20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifso20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"FSO322"}}